Literature DB >> 8564103

8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro.

I Kawikova1, P J Barnes, T Takahashi, S Tadjkarimi, M H Yacoub, M G Belvisi.   

Abstract

8-Epi-prostaglandin F2 alpha (8-epi-PGF2 alpha) is an F2-isoprostane formed via a noncyclooxygenase pathway. We investigated whether 8-epi-PGF2 alpha has any effects on isolated guinea-pig and human airway smooth-muscle tone, and characterized the receptor involved in these effects. Cumulative concentration responses to 8-epi-PGF2 alpha in the absence or presence of prostanoid TP- and EP1-receptors antagonists (ICI 192, 605 and AH 6809, respectively) were compared with the responses to U46619 (a thromboxane A2 mimetic) and PGF2 alpha. 8-epi-PGF2 alpha contracted airway smooth muscle with a rank order of potency of U46619 > PGF alpha > 8-epi-PGF2 alpha for guinea pig and U46619 > 8-epi-PGF2 alpha > PGF2 alpha for human smooth muscle. ICI 192,605 inhibited guinea-pig tracheal contraction produced by U46619 (pA2 = 10.0) with a similar potency to its inhibition of the contraction induced by 8-epi-PGF2 alpha (apparent pKB = 10.2, 10.3), but not that induced by PGF2 alpha (apparent pKB = 6.6). AH 6809 inhibited contraction induced by PGF2 alpha (pA2 = 6.6) with a greater potency than contraction induced by U46619 (apparent pKB = 5.1, 5.2) or 8-epi-PGF2 alpha (apparent pKB = 5.3). In human airways, ICI 192,605 inhibited contraction induced by U46619 and 8-epi-PGF2 alpha with apparent pKB values of 9.5 and 9.4, respectively, and AH 6809 inhibited contraction induced by 8-epi-PGF2 alpha with apparent pKB values of 5.7 and 5.4. We conclude that 8-epi-PGF2 alpha contracts human and guinea-pig airways via prostanoid TP receptors. However, if 8-epi-PGF2 alpha is formed in asthma, its production, unlike that of other prostanoids, would not be inhibited by cyclooxygenase inhibitors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8564103     DOI: 10.1164/ajrccm.153.2.8564103

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  21 in total

1.  Characterization of the effects of isoprostanes on platelet aggregation in human whole blood.

Authors:  J H Cranshaw; T W Evans; J A Mitchell
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 2.  Pathophysiology of bronchoconstriction: role of oxidatively damaged DNA repair.

Authors:  Attila Bacsi; Lang Pan; Xueqing Ba; Istvan Boldogh
Journal:  Curr Opin Allergy Clin Immunol       Date:  2016-02

Review 3.  Pharmacologic interventions for the prevention and treatment of retinopathy of prematurity.

Authors:  Kay D Beharry; Gloria B Valencia; Douglas R Lazzaro; Jacob V Aranda
Journal:  Semin Perinatol       Date:  2016-01-29       Impact factor: 3.300

4.  Vasoconstrictor actions of isoprostanes via tyrosine kinase and Rho kinase in human and canine pulmonary vascular smooth muscles.

Authors:  L J Janssen; M Premji; S Netherton; J Coruzzi; H Lu-Chao; P G Cox
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 5.  Genes of innate immunity and the biological response to inhaled ozone.

Authors:  Zhuowei Li; Robert M Tighe; Feifei Feng; Julie G Ledford; John W Hollingsworth
Journal:  J Biochem Mol Toxicol       Date:  2012-11-20       Impact factor: 3.642

6.  Effects of some isoprostanes on the human umbilical artery in vitro.

Authors:  L Oliveira; N A Stallwood; D J Crankshaw
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

7.  Prostaglandin E₂ suppresses allergic sensitization and lung inflammation by targeting the E prostanoid 2 receptor on T cells.

Authors:  Zbigniew Zasłona; Katsuhide Okunishi; Emilie Bourdonnay; Racquel Domingo-Gonzalez; Bethany B Moore; Nicholas W Lukacs; David M Aronoff; Marc Peters-Golden
Journal:  J Allergy Clin Immunol       Date:  2013-09-24       Impact factor: 10.793

8.  Regulation of [³H]d-aspartate release by the 5-F(2t)-isoprostane and its 5-epimer in isolated bovine retina.

Authors:  Jamal Jamil; Ashley Wright; Na'cara Harrison; Edem Kegey; Arnecia Faye Flowers; Namonique Jarell Flyod; Casey Kotera; Alexandre Guy; Jean-Marie Galano; Thierry Durand; Ya Fatou Njie-Mbye; Sunny E Ohia; Catherine A Opere
Journal:  Neurochem Res       Date:  2011-11-13       Impact factor: 3.996

Review 9.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

Review 10.  Clinical use of exhaled biomarkers in COPD.

Authors:  Philip O'Reilly; William Bailey
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.